You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The move is intended to increase testing for COVID-19 and may help conserve resources, which were a major problem during the height of the pandemic.
More than a dozen studies have been published to date directly comparing molecular diagnostic COVID-19 tests, with some detecting differences, mostly in sensitivity.
A handful of recently published trials suggest that use of the pneumonia panel could lead to more targeted therapy delivered more quickly than standard methods.
The acquisition will round out BD's molecular portfolio and be complementary to the firm's Veritor immunoassay system, according to executives.
With the US now awash in positive samples, assay developers seeking authorization will no longer be allowed to use contrived samples.
The firm's Continuum system is fully automated and performs the entire digital PCR workflow in a single instrument.
The partners received Emergency Use Authorization last week for a test that uses oral fluids, and the lab has capacity to test up to 10,000 samples per day.
The agency plans to work with a number of partners to develop codes that will describe tests and results to standardize data collection.
MBS has developed a compact endpoint PCR system which can test more than 22,000 patient samples per day by performing eight-minute thermal cycling.
The Atila iAMP test was granted Emergency Use Authorization earlier this week and is being evaluated in multiple US labs.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.